CA3030257A1 - Antibody for anti-claudin 18a2 and use thereof - Google Patents

Antibody for anti-claudin 18a2 and use thereof Download PDF

Info

Publication number
CA3030257A1
CA3030257A1 CA3030257A CA3030257A CA3030257A1 CA 3030257 A1 CA3030257 A1 CA 3030257A1 CA 3030257 A CA3030257 A CA 3030257A CA 3030257 A CA3030257 A CA 3030257A CA 3030257 A1 CA3030257 A1 CA 3030257A1
Authority
CA
Canada
Prior art keywords
seq
antibody
cell
amino acid
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3030257A
Other languages
English (en)
French (fr)
Inventor
Peng Wang
Hua Jiang
Linlin YANG
Zhimin Shi
Huamao Wang
Zonghai Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crage Medical Co Ltd
Original Assignee
Shanghai Cancer Institute
Carsgen Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2017/082024 external-priority patent/WO2017186121A1/zh
Application filed by Shanghai Cancer Institute, Carsgen Therapeutics Ltd filed Critical Shanghai Cancer Institute
Publication of CA3030257A1 publication Critical patent/CA3030257A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
CA3030257A 2016-07-08 2017-07-10 Antibody for anti-claudin 18a2 and use thereof Pending CA3030257A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610536449.9 2016-07-08
CN201610536449 2016-07-08
CNPCT/CN2017/082024 2017-04-26
PCT/CN2017/082024 WO2017186121A1 (zh) 2016-04-26 2017-04-26 一种改善免疫应答细胞功能的方法
PCT/CN2017/092381 WO2018006882A1 (zh) 2016-07-08 2017-07-10 抗密蛋白18a2的抗体及其应用

Publications (1)

Publication Number Publication Date
CA3030257A1 true CA3030257A1 (en) 2018-01-11

Family

ID=60912336

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3030257A Pending CA3030257A1 (en) 2016-07-08 2017-07-10 Antibody for anti-claudin 18a2 and use thereof

Country Status (13)

Country Link
US (2) US11111295B2 (https=)
EP (1) EP3483182B1 (https=)
JP (1) JP7587921B2 (https=)
KR (1) KR102723896B1 (https=)
CN (1) CN109790222B (https=)
AU (1) AU2017294276B2 (https=)
BR (1) BR112019000327A8 (https=)
CA (1) CA3030257A1 (https=)
CL (1) CL2019000061A1 (https=)
ES (1) ES2979068T3 (https=)
IL (1) IL264144B2 (https=)
SG (1) SG11201900171QA (https=)
WO (1) WO2018006882A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020023679A1 (en) * 2018-07-25 2020-01-30 Accurus Biosciences, Inc. Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof
WO2020205331A1 (en) * 2019-03-29 2020-10-08 Phanes Therapeutics, Inc. Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
US20210261658A1 (en) * 2018-08-22 2021-08-26 Reyoung (Suzhou) Biology Science & Technology Co., Ltd Anti-human claudin 18.2 monoclonal antibody and application thereof
US20230192840A1 (en) * 2018-12-28 2023-06-22 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody and use thereof

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017294276B2 (en) * 2016-07-08 2024-08-01 Crage Medical Co., Limited Antibody for anti-claudin 18A2 and use thereof
KR20200143672A (ko) 2018-02-02 2020-12-24 카르스젠 테라퓨틱스 컴퍼니, 리미티드 세포 면역 치료의 조합
JP7398380B2 (ja) 2018-03-08 2023-12-14 フェインズ セラピューティクス，インコーポレーテッド 抗クローディン１８．２抗体及びその使用
CN111989344A (zh) * 2018-03-09 2020-11-24 科济生物医药（上海）有限公司 用于治疗肿瘤的方法和组合物
US11485782B2 (en) * 2018-03-14 2022-11-01 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
CN112074600A (zh) * 2018-05-03 2020-12-11 科济生物医药（上海）有限公司 免疫效应细胞及其应用
CA3100446A1 (en) 2018-05-15 2019-11-21 Carsgen Therapeutics Co., Ltd. Genetically engineered cell and application thereof
SG11202007074PA (en) * 2018-05-18 2020-08-28 Lanova Medicines Ltd Company Anti-claudin 18.2 antibodies and uses thereof
KR20210055034A (ko) 2018-07-24 2021-05-14 카파 테라퓨틱스 리미티드 면역 이펙터 세포를 사용하여 종양을 치료하는 방법
EP3878863A4 (en) * 2018-08-27 2022-06-22 Nanjing Sanhome Pharmaceutical Co., Ltd. ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE
CN109206524B (zh) * 2018-09-25 2022-04-05 山东兴瑞生物科技有限公司 抗Claudin18A2嵌合抗原受体、其修饰的T细胞及T细胞制备方法和用途
US20220033491A1 (en) * 2018-09-30 2022-02-03 Cafa Therapeutics Limited Combination therapy of cldn18 antibody and chemotherapy drugs
US20230158071A1 (en) 2018-12-07 2023-05-25 Crage Medical Co., Limited Tumor combined immunotherapy
JP7458399B2 (ja) * 2018-12-07 2024-03-29 ゼットリップ ホールディング リミテッド 抗クローディン抗体及びそれらの使用
CN113227146B (zh) * 2018-12-28 2024-03-01 南京金斯瑞生物科技有限公司 密蛋白18.2结合部分和其用途
KR20210126008A (ko) 2019-01-07 2021-10-19 카르스젠 테라퓨틱스 컴퍼니, 리미티드 세포 면역 치료의 조합
CN114106183B (zh) * 2019-01-15 2023-06-23 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
US20220127372A1 (en) 2019-02-01 2022-04-28 Cafa Therapeutics Limited Tcr fusion protein and cell expressing tcr fusion protein
CA3128502A1 (en) * 2019-02-01 2020-08-06 Novarock Biotherapeutics, Ltd. Anti-claudin 18 antibodies and methods of use thereof
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
JP7654557B2 (ja) * 2019-03-27 2025-04-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｔｎ－ＭＵＣ１キメラ抗原受容体（ＣＡＲ）Ｔ細胞療法
MX2021011489A (es) * 2019-04-01 2021-10-22 Jiangsu Hengrui Medicine Co Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
WO2020211792A1 (zh) * 2019-04-19 2020-10-22 康诺亚生物医药科技（成都）有限公司 肿瘤治疗剂及其应用
WO2020228806A1 (zh) 2019-05-16 2020-11-19 齐鲁制药有限公司 针对密蛋白18a2的抗体及其应用
CN111978402B (zh) * 2019-05-24 2022-06-28 三优生物医药(上海)有限公司 新型cldn18.2结合分子
WO2020238730A1 (zh) * 2019-05-24 2020-12-03 三优生物医药(上海)有限公司 新型cldn18.2结合分子
EP3929214A4 (en) 2019-05-30 2022-06-22 Shandong Boan Biotechnology Co., Ltd. ANTIBODY OR CHIMERIC ANTIGEN RECEPTOR DIRECTED AGAINST CLAUDIN 18.2
JP2022541435A (ja) * 2019-07-17 2022-09-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン１８抗体及びがんを処置する方法
PE20211147A1 (es) 2019-08-12 2021-06-28 I Mab Biopharma Us Ltd Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso
CN112574307B (zh) 2019-09-29 2023-11-28 迈威(上海)生物科技股份有限公司 抗人Claudin18.2抗体及其应用
BR112022008653A2 (pt) 2019-11-05 2022-07-19 Lanova Medicines Ltd Conjugado anticorpo-fármaco, método para tratar câncer, e, uso do conjugado anticorpo-fármaco
US20230000918A1 (en) * 2019-11-29 2023-01-05 Suzhou Nova Therapeutics Co. Ltd Chimeric antigen receptors, compositions and applications thereof
EP4069738A1 (en) 2019-12-06 2022-10-12 SOTIO Biotech a.s. Humanized cldn18.2 antibodies
CN114901365B (zh) 2019-12-23 2025-07-15 斯迪安生物技术公司 肿瘤特异性密蛋白18.2抗体
CA3166498A1 (en) * 2020-01-03 2021-07-08 Crage Medical Co., Limited Anti-claudin 18.2 antibody and use thereof
US20230096452A1 (en) * 2020-02-10 2023-03-30 Shanghai Escugen Biotechnology Co., Ltd. Claudin 18.2 antibody and use thereof
WO2021173307A1 (en) * 2020-02-25 2021-09-02 Gensun Biopharma Inc. Trispecific t cell engagers
IL298184A (en) * 2020-05-15 2023-01-01 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Antibody drug conjugate, preparation method therefor and use thereof
CN115943162A (zh) * 2020-06-19 2023-04-07 信达生物制药(苏州)有限公司 抗Claudin18.2抗体以及其用途
CN113929780A (zh) * 2020-07-13 2022-01-14 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
CN111961135B (zh) * 2020-07-13 2022-08-16 北京亦庄国际蛋白药物技术有限公司 一种用于预防或治疗癌症的抗体
CN111704669B (zh) * 2020-07-13 2022-05-13 北京凯因科技股份有限公司 一种用于治疗晚期胃癌的抗cldn18全人源化抗体
CN114222761B (zh) * 2020-07-14 2024-02-20 浙江道尔生物科技有限公司 一种抗cld18a2的单域抗体
EP4194055A4 (en) 2020-08-07 2025-02-12 CRAGE medical Co., Limited MANIPULATED CELLS AND METHODS FOR MANIPULATING CELLS
US20240034784A1 (en) * 2020-09-30 2024-02-01 Nanjing GenScript Biotech Co., Ltd. Antibodies targeting human claudin 18.2 and uses thereof
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
WO2022140388A1 (en) 2020-12-21 2022-06-30 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
CA3199830A1 (en) 2020-12-23 2022-06-30 Lukas BAMMERT Tumor-specific claudin 18.2 antibody-drug conjugates
CA3204417A1 (en) 2021-01-29 2022-08-04 Allogene Therapeutics, Inc. Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
EP4299593A4 (en) * 2021-04-02 2025-12-10 Oricell Therapeutics Co Ltd CLDN18.2 ANTIGEN-BINDING PROTEIN AND ITS USE
WO2022214089A1 (zh) 2021-04-08 2022-10-13 克莱格医学有限公司 细胞免疫治疗的应用
CN117480247A (zh) * 2021-04-15 2024-01-30 恺兴生命科技(上海)有限公司 嵌合t细胞受体及其应用
CN117157105A (zh) 2021-05-08 2023-12-01 荣昌生物制药(烟台)股份有限公司 一种抗Claudin18.2抗体及其抗体药物偶联物
US20250269028A1 (en) 2021-06-29 2025-08-28 Carsgen Therapeutics Co., Ltd Chimeric polypeptide for regulating cell physiological activity
CN114907482B (zh) * 2021-09-03 2023-02-14 深圳市先康达生命科学有限公司 靶向人Claudin18.2蛋白的单克隆抗体及其应用
CN118139888A (zh) * 2021-11-05 2024-06-04 正大天晴药业集团股份有限公司 抗cldn18.2抗体及其用途
WO2023213280A1 (zh) * 2022-05-06 2023-11-09 上海先博生物科技有限公司 靶向cldn18.2的嵌合抗原t细胞受体及其应用
CN120484126B (zh) * 2022-07-28 2025-11-18 乐普创一生物科技（上海）有限公司 抗MerTK抗体及其用途
JP2025525779A (ja) 2022-07-29 2025-08-07 アロジーン セラピューティクス，インコーポレイテッド 免疫細胞の認識を低減させるために遺伝子発現が低下した、操作された細胞
AU2023362746A1 (en) * 2022-10-20 2025-06-05 Microcrispr Pvt Ltd. Attenuation of cytokine release syndrome in immunotherapy
AU2023362748A1 (en) * 2022-10-20 2025-06-05 Microcrispr Pvt Ltd. Attenuation of cytokine release syndrome in immunotherapy
AU2023362749A1 (en) * 2022-10-20 2025-06-05 Microcrispr Pvt Ltd. Attenuation of cytokine release syndrome in immunotherapy
JP2025535444A (ja) * 2022-10-20 2025-10-24 マイクロ クリスパー プライベート リミテッド 免疫療法におけるサイトカイン放出症候群の軽減
JP2025535441A (ja) * 2022-10-20 2025-10-24 マイクロ クリスパー プライベート リミテッド 免疫療法におけるサイトカイン放出症候群の軽減
KR20250129814A (ko) 2023-01-18 2025-08-29 타이리간드 바이오사이언스 (상하이) 리미티드 항체-약물 접합체 및 이의 용도
WO2025026347A1 (en) * 2023-07-31 2025-02-06 Nanjing Legend Biotech Co., Ltd. Chimeric cytokine receptors and methods of use thereof
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells
CN117430708B (zh) * 2023-12-21 2024-04-09 苏州近岸蛋白质科技股份有限公司 一种抗Claudin18.2抗体
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
CN120005046B (zh) * 2025-04-18 2025-09-02 深锐(天津)生物医学有限公司 双靶点嵌合抗原受体联合pd-1与il-21融合蛋白

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
CN120137055A (zh) * 2014-07-17 2025-06-13 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
CN105331585A (zh) * 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
PE20181302A1 (es) 2015-12-04 2018-08-09 Abbvie Stemcentrx Llc Nuevos anticuerpos anti-claudina y sus metodos de uso
WO2017186121A1 (zh) * 2016-04-26 2017-11-02 科济生物医药（上海）有限公司 一种改善免疫应答细胞功能的方法
AU2017294276B2 (en) * 2016-07-08 2024-08-01 Crage Medical Co., Limited Antibody for anti-claudin 18A2 and use thereof
CN111989344A (zh) * 2018-03-09 2020-11-24 科济生物医药（上海）有限公司 用于治疗肿瘤的方法和组合物
US20220033491A1 (en) * 2018-09-30 2022-02-03 Cafa Therapeutics Limited Combination therapy of cldn18 antibody and chemotherapy drugs
KR20210126008A (ko) * 2019-01-07 2021-10-19 카르스젠 테라퓨틱스 컴퍼니, 리미티드 세포 면역 치료의 조합
WO2022033483A1 (zh) * 2020-08-10 2022-02-17 佧珐药业有限公司 多功能的免疫效应细胞及其应用

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020023679A1 (en) * 2018-07-25 2020-01-30 Accurus Biosciences, Inc. Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof
US20210214433A1 (en) * 2018-07-25 2021-07-15 Accurus Biosciences, Inc. Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof
US12054543B2 (en) * 2018-07-25 2024-08-06 Accurus Biosciences, Inc. CLDN 18.2-specific monoclonal antibodies and methods of use thereof
US20210261658A1 (en) * 2018-08-22 2021-08-26 Reyoung (Suzhou) Biology Science & Technology Co., Ltd Anti-human claudin 18.2 monoclonal antibody and application thereof
US12129296B2 (en) * 2018-08-22 2024-10-29 Reyoung (Suzhou) Biology Science & Technology Co., Ltd Anti-human claudin 18.2 monoclonal antibody and application thereof
US20230192840A1 (en) * 2018-12-28 2023-06-22 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody and use thereof
US12297265B2 (en) * 2018-12-28 2025-05-13 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody and use thereof
WO2020205331A1 (en) * 2019-03-29 2020-10-08 Phanes Therapeutics, Inc. Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof

Also Published As

Publication number Publication date
IL264144A (en) 2019-02-28
AU2017294276B2 (en) 2024-08-01
JP7587921B2 (ja) 2024-11-21
CN109790222B (zh) 2022-03-15
US20190233511A1 (en) 2019-08-01
US11111295B2 (en) 2021-09-07
AU2017294276A1 (en) 2019-02-28
CL2019000061A1 (es) 2019-05-03
IL264144B2 (en) 2023-11-01
JP2019531084A (ja) 2019-10-31
BR112019000327A8 (pt) 2022-10-18
EP3483182A4 (en) 2020-07-29
ES2979068T3 (es) 2024-09-24
RU2019101430A (ru) 2020-08-10
KR102723896B1 (ko) 2024-11-01
KR20190038564A (ko) 2019-04-08
EP3483182B1 (en) 2024-05-08
EP3483182A1 (en) 2019-05-15
CN109790222A (zh) 2019-05-21
BR112019000327A2 (pt) 2019-08-13
US20220185880A1 (en) 2022-06-16
RU2019101430A3 (https=) 2021-05-17
NZ750420A (en) 2025-06-27
IL264144B1 (en) 2023-07-01
SG11201900171QA (en) 2019-02-27
WO2018006882A1 (zh) 2018-01-11

Similar Documents

Publication Publication Date Title
US20220185880A1 (en) Antibody for anti-claudin 18a2 and use thereof
AU2019253562B2 (en) Methods and compositions comprising a viral vector for expression of a transgene and an effector
US11484552B2 (en) Use of trans-signaling approach in chimeric antigen receptors
AU2020202726A1 (en) Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3856782A1 (en) Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
CN118146379A (zh) 一种改善免疫应答细胞功能的方法
AU2018221110B9 (en) Antibody Targeting IL-13RA2 and Use Thereof
EP3194443A1 (en) Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
JP2020530269A (ja) 変異ｃｄ２８共刺激ドメインを有するキメラ抗原受容体
WO2020223327A1 (en) Antigen specific cd19-targeted car-t cells
AU2019312411A1 (en) Nef-containing T cells and methods of producing thereof
WO2018149358A1 (zh) 靶向il-13ra2的抗体及其应用
RU2793445C2 (ru) Антитело против клаудина 18а2 и его применение
HK40002280B (zh) 抗密蛋白18a2的抗体及其应用
HK40002280A (zh) 抗密蛋白18a2 的抗体及其应用
HK40017077A (en) Il-13ra2-targeted antibody and application thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220711

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240916

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250116

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250213